Dalteparin detailed information: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{CMG}} | {{CMG}} | ||
'''For patient information, click [[Dalteparin (patient information)|here]]''' | '''For patient information, click [[Dalteparin (patient information)|here]]''' | ||
| Line 11: | Line 8: | ||
The CLOT study, published in 2003, showed that in patients with malignancy and acute venous thromboembolism, dalteparin was more effective than [[coumarin]] in reducing the risk of recurrent embolic events.<ref>{{cite journal | author=Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M | title=Low-molecular-weight heparin versus a [[coumarin]] for the prevention of recurrent venous thromboembolism in patients with cancer | journal=N Engl J Med | year=2003 | pages=146-53 | volume=349 | issue=2 | id=PMID 12853587}} | The CLOT study, published in 2003, showed that in patients with malignancy and acute venous thromboembolism, dalteparin was more effective than [[coumarin]] in reducing the risk of recurrent embolic events.<ref>{{cite journal | author=Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M | title=Low-molecular-weight heparin versus a [[coumarin]] for the prevention of recurrent venous thromboembolism in patients with cancer | journal=N Engl J Med | year=2003 | pages=146-53 | volume=349 | issue=2 | id=PMID 12853587}} | ||
</ref> | </ref> | ||
==See also== | |||
*[[Heparin]] | |||
==References== | ==References== | ||
Revision as of 05:59, 10 September 2011
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
For patient information, click here
Overview
Dalteparin is a low molecular weight heparin. It is marketed as Fragmin by Eisai. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of deep vein thrombosis and pulmonary embolism.
The CLOT study, published in 2003, showed that in patients with malignancy and acute venous thromboembolism, dalteparin was more effective than coumarin in reducing the risk of recurrent embolic events.[1]